Our findings may provide valuable information on the underlying molecular mechanism of resistance of LSCs to G9a inhibition, along with potential therapeutic targets to overcome AML resistance to G9a inhibitors and to eradicate LSCs. This evidence concerns the gene EHMT2 and acute myeloid leukemia.